IndraLab
Statements
Hydroxychloroquine inhibits KCNH2. 28 / 29
1
|
5
23
eidos
"HCQ is known to block Kv11.1 ( HERG ) and induce prolong QT , thus predisposing the patient to malignant arrhythmia such as torsade de points.70 , 71 However , studies have found that these arrhythmic toxicities are mostly encountered in chronic use with multiple concomitant QT prolonging agents , metabolic abnormalities , renal insufficiency , as well as medication overdose.72 , 73 Because the use of HCQ in COVID-19 has relatively short duration , the risk of developing significant arrhythmia is relatively low ."
reach
"Additionally, hERG channel inhibition by HCQ is stronger at lower extracellular K+ concentrations, [33] pointing to the need to correct or prevent hypokalaemia during and immediately after clinical therapy with this drug.The direct correlation between the QTc interval and age seen in our data has already been described in the literature [35]."
reach
"We found that the enantiomers of HCQ selectively inhibit K 2.1 channels and, less potently, hERG channels, and significantly alter several cardinal AP metrics at concentrations about one order of magnitude above the free plasma concentrations circulating at therapeutically effective doses.2
Material and methods."
reach
"Additionally, for hydroxychloroquine, a recent study pointed out that hydroxychloroquine could lead to unwanted QT interval prolongation by blocking the KCNH2 encoded hERG and Kv11.1 potassium channel, thereby increasing the risk of drug induced torsade de pointes and sudden cardiac death."
reach
"Recently, a study of the effects of COVID-19 drugs chloroquine and hydroxychloroquine on blocking the hERG potassium channel showed that these drugs acutely and severely inhibited the hERG current, but remdesivir increased the I with promoted hERG maturation when acting alone (Szendrey et al., 2021)."